These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36327624)

  • 61. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
    Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
    Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
    JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
    Williamson M; Press DJ; Hansen SA; Tomar A; Jhuti GS; Revil C; Gururaj K
    Breast Cancer; 2024 Jan; 31(1):84-95. PubMed ID: 37907759
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
    Brown EL; Shmuel S; Mandleywala K; Panikar SS; Berry NK; Rao Y; Zidel A; Lewis JS; Pereira PMR
    J Nucl Med; 2023 Oct; 64(10):1638-1646. PubMed ID: 37385676
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
    Perez EA; Hurvitz SA; Amler LC; Mundt KE; Ng V; Guardino E; Gianni L
    Breast Cancer Res; 2014 May; 16(3):R50. PubMed ID: 24887458
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
    Guarneri V; Passos Coelho JL; Duhoux FP; Egle D; García-Sáenz JÁ; Penault-Llorca F; Selander K; Wildiers H; Zaman K; Laeis P; Lucerna M; Pierga JY
    Future Oncol; 2024; 20(18):1237-1250. PubMed ID: 38592002
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
    Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
    Breast Cancer Res Treat; 2024 Sep; 207(2):253-261. PubMed ID: 38797792
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis.
    Pedersini R; Buffoni M; Petrelli F; Ghidini A; di Mauro P; Amoroso V; Parati MC; Laini L; Cosentini D; Schivardi G; Ippolito G; Berruti A; Laganà M
    Clin Breast Cancer; 2024 Jul; 24(5):411-420. PubMed ID: 38734491
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
    Diaby V; Alqhtani H; van Boemmel-Wegmann S; Wang CY; Ali AA; Balkrishnan R; Ko Y; Palacio S; de Lima Lopes G
    Breast; 2020 Feb; 49():141-148. PubMed ID: 31805500
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
    Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
    Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine.
    Modi ND; Sorich MJ; Rowland A; McKinnon RA; Koczwara B; Wiese MD; Hopkins AM
    Clin Breast Cancer; 2020 Apr; 20(2):e220-e228. PubMed ID: 31892489
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
    Krop IE; Im SA; Barrios C; Bonnefoi H; Gralow J; Toi M; Ellis PA; Gianni L; Swain SM; Im YH; De Laurentiis M; Nowecki Z; Huang CS; Fehrenbacher L; Ito Y; Shah J; Boulet T; Liu H; Macharia H; Trask P; Song C; Winer EP; Harbeck N
    J Clin Oncol; 2022 Feb; 40(5):438-448. PubMed ID: 34890214
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
    Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
    PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
    Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
    Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
    Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
    J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.